Icecure Medical (ICCM) has released an update.
Icecure Medical’s mid-year financial report reveals a slight decrease in total assets from $16.41 million at the end of 2023 to $15.36 million as of June 30, 2024, along with a reduction in shareholders’ equity from $12.16 million to $10.61 million over the same period. The company reports a net loss of $6.69 million for the first half of 2024, with a basic and diluted net loss per share of $0.14. These figures reflect challenges the company faces, as well as the impact of its ongoing investments in research and development.
For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.
